{"id":3646,"date":"2018-11-20T17:33:20","date_gmt":"2018-11-20T12:03:20","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3646"},"modified":"2021-07-24T12:57:07","modified_gmt":"2021-07-24T07:27:07","slug":"notizia-81","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-81","title":{"rendered":"Notizia"},"content":{"rendered":"

Gene editing, a possible treatment, for inherited kidney disease<\/span><\/b><\/p>\n

Joubert syndrome<\/strong>, an inherited brain disorder that causes kidney failure in patients. This requires a transplant or dialysis. A mutation in the gene CEP290 causes the inherited form of kidney disease and scientists in the U.K. to apprise of having an early proof of gene editing called \u201cexon skipping<\/strong>\u201d that can correct the error. The researchers at Newcastle University<\/strong> used a synthetic strand of DNA to deceive cells into bypassing the damaging CEP290<\/strong> mutation. They used kidney cells taken from a 19-year-old patient with Joubert syndrome for their early testing of the technique.<\/span><\/p>\n

The New England Journal of Medicine (NEJM) paper buoys peanut allergy drug prospects of Aimmune <\/span><\/b><\/p>\n

The phase 3 trial of oral immunotherapy AR101<\/strong> for peanut<\/strong> allergy<\/strong><\/a> of<\/span> Aimmune, t<\/span><\/b>he biotechnology company, <\/span>has been published and slated for FDA<\/strong> filing soon.<\/span> The PALISADE study indicates that children who were classified as highly allergic to peanuts were able to tolerate a much higher exposure to peanut protein after treatment with AR101\u2014a 12% defatted peanut flour preparation\u2014at gradually increasing doses up to a threshold of 300 mg per day. With the 550-patient study, more than half of those patients were able to tolerate eating 600 mg of peanut protein, compared to the placebo group.<\/span><\/p>\n

\u00a0Axumin of Blue Earth study indicates promise in glioma PET scans<\/span><\/b><\/p>\n

The phase 3 study of molecular imaging firm Blue Earth Diagnostics<\/strong> showed that its Axumin<\/strong> for PET<\/strong> scans could help in the diagnosis of glioma patients. Axumin, consisting of the synthetic amino acid fluciclovine<\/strong> tagged with a fluoride radioisotope, has\u00a0the FDA<\/strong> approval for PET scans in treating men suspected with prostate cancer recurrence, based on blood measurements of the prostate<\/a>-specific antigen biomarker. In the image-evaluation study, the injection was used to picture, there is an increase in amino acid transport in tumours such as glioma, compared to MRI<\/strong> scans alone, for the detection and continued assessment of the malignant brain tumours.<\/span><\/p>\n

Quanterix gets into oncology research with benchtop imager<\/span><\/b><\/p>\n

Quanterix<\/strong>, the molecular diagnostic firm,<\/b> is extending its blood biomarker<\/strong> testing business into oncology, giving an early access program to its benchtop imager and a new 10-plex assay panel for cancer research and drug development. The SP-X<\/strong> molecular imaging of the company uses chemiluminescent planar array technology under its Simoa Sensitivity assay platform label. It is for measurement of concentrations of circulating cytokines and immunological biomarkers.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Gene editing, a possible treatment, for inherited kidney disease Joubert syndrome, an inherited brain disorder that causes kidney failure in patients. This requires a transplant or dialysis. A mutation in the gene CEP290 causes the inherited form of kidney disease and scientists in the U.K. to apprise of having an early proof of gene editing […]<\/p>\n","protected":false},"author":1,"featured_media":3649,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2194,2192,2196,2201,2195,2191,2189,704,2198,2188,2199,2190,2193,2197,2200,2202],"industry":[17225],"therapeutic_areas":[17239,17238,17227,17278],"class_list":["post-3646","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-aimmune","tag-ar101","tag-axumin","tag-blood-biomarker","tag-blue-earth-diagnostics","tag-cep290","tag-exon-skipping","tag-fda","tag-fluciclovine","tag-joubert-syndrome","tag-mri","tag-newcastle-university","tag-peanut-allergy","tag-pet","tag-quanterix","tag-sp-x","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-genetic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"\nNotizia 20\/11\/2018 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Joubert syndrome, an inherited brain disorder that causes kidney failure in patients. This requires a transplant or dialysis. A mutation in the gene.....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-81\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 20\/11\/2018 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Joubert syndrome, an inherited brain disorder that causes kidney failure in patients. This requires a transplant or dialysis. A mutation in the gene.....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-81\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-20T12:03:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"752\" \/>\n\t<meta property=\"og:image:height\" content=\"501\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 20\/11\/2018 - DelveInsight Business Research","description":"Joubert syndrome, an inherited brain disorder that causes kidney failure in patients. This requires a transplant or dialysis. A mutation in the gene.....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-81","og_locale":"en_US","og_type":"article","og_title":"Notizia 20\/11\/2018 - DelveInsight Business Research","og_description":"Joubert syndrome, an inherited brain disorder that causes kidney failure in patients. This requires a transplant or dialysis. A mutation in the gene.....","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-81","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-11-20T12:03:20+00:00","article_modified_time":"2021-07-24T07:27:07+00:00","og_image":[{"width":752,"height":501,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-81","url":"https:\/\/www.delveinsight.com\/blog\/notizia-81","name":"Notizia 20\/11\/2018 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-81#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-81#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg","datePublished":"2018-11-20T12:03:20+00:00","dateModified":"2021-07-24T07:27:07+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Joubert syndrome, an inherited brain disorder that causes kidney failure in patients. This requires a transplant or dialysis. A mutation in the gene.....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-81"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-81#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg","width":752,"height":501,"caption":"patent ductus arteriosus"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Aimmune<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AR101<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Axumin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">blood biomarker<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Blue Earth Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CEP290<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">exon skipping<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">fluciclovine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Joubert syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MRI<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Newcastle University<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">peanut allergy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PET<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Quanterix<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">SP-X<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aimmune<\/span>","<span class=\"advgb-post-tax-term\">AR101<\/span>","<span class=\"advgb-post-tax-term\">Axumin<\/span>","<span class=\"advgb-post-tax-term\">blood biomarker<\/span>","<span class=\"advgb-post-tax-term\">Blue Earth Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">CEP290<\/span>","<span class=\"advgb-post-tax-term\">exon skipping<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">fluciclovine<\/span>","<span class=\"advgb-post-tax-term\">Joubert syndrome<\/span>","<span class=\"advgb-post-tax-term\">MRI<\/span>","<span class=\"advgb-post-tax-term\">Newcastle University<\/span>","<span class=\"advgb-post-tax-term\">peanut allergy<\/span>","<span class=\"advgb-post-tax-term\">PET<\/span>","<span class=\"advgb-post-tax-term\">Quanterix<\/span>","<span class=\"advgb-post-tax-term\">SP-X<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 20, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 20, 2018 5:33 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"patent ductus arteriosus","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3646"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3646\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3649"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3646"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3646"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}